Summary of KOSPI200 & KOSDAQ150 Upcoming Reshuffle
As I said in my earlier comment, Samsung Biologics Co., Ltd (207940 KS) seems to be benefiting a lot from its inclusion in KOSPI200 index. Perhaps...
2.2k Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
784 Views
WuXi Biologics: Pass on This Valuation
The company's underwriters have announced a price range of HK$18.60 - HK$20.60 which implies a market cap of US$2.7-3.0 billion. We recommend...
758 Views
WuXi Biologics: Updated Valuation Data
We have heard that WuXi Biologics' bankers are preparing to move forward with the offering though a PHIP has not been posted yet. The updated...
700 Views
Samsung Restructuring Update - Newly Emerging Scenario & Regulatory Pushes
Samsung restructuring debate doesn't really seem to have ended. Among Korea's local investors, this just continues to be one of the topics that are...
288 Views